Mode
Text Size
Log in / Sign up
N/A Completed N=211

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Source: ClinicalTrials.gov NCT00904371 ↗
Enrolled (actual)
211
Serious AEs
1.0%
Results posted
Aug 2012
Primary outcomePrimary: Change From Baseline in Systolic Blood Pressure (SBP) — -22.6 mm Hg

Summary

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Systolic Blood Pressure (SBP)
-22.6 —
PRIMARY
Change From Baseline in Diastolic Blood Pressure (DBP)
-10.1 —
PRIMARY
Change From Baseline in SCORE (10 Year Risk for Fatal Cardiovascular Event)
-3.9 —
PRIMARY
Change From Baseline in Framingham CVD Risk Assessment Score
-7.6 —
PRIMARY
Change From Baseline in Framingham Stroke Risk Assessment Score
-3.6 —
PRIMARY
Change From Baseline in Risk Assessment According to ESH/ESC Guidelines
18; 7; -13; -12 —
SECONDARY
Pecentage of Patients That Achieved Target Blood Pressure (BP) Values According to ESH/ESC
32.8; 67.2 —
SECONDARY
Additional Antihypertensive Treatment Pattern at Visit 3 (End of Study)
19; 11.2; 32.2; 36.1; 9.3 —
SECONDARY
Change in Heart Rate From Baseline to Study End
-3.2 —
SECONDARY
Number of Patients With Adverse Events (AE)
4 —
SECONDARY
Number of Participants Not Completing Study
2; 4; 2; 1 —

Eligibility Criteria

Inclusion criteria

  • diagnosis of essential arterial hypertension (BP>140/90 mm HG or BP>130/80 mm Hg for diabetic patients)
  • at least an additional cardiovascular risk factor

Exclusion criteria

  • hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market
  • pregnancy and lactation
  • diseases involving biliary obstruction
  • severe liver impairment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00904371). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search